Researchers showed that modeling of intermittent ceralasertib treatment in mouse tumor models revealed CD8+ T-cell dependent antitumor activity, which was separate from the effects on tumor cells.
[Nature Communications]
Home Newsletters Immune Regulation News The ATR Inhibitor Ceralasertib Potentiates Cancer Checkpoint Immunotherapy by Regulating the Tumor...
